BACKGROUND: Overexpression of the ERG protein is highly prevalent in prostate cancer (PCa) and commonly results from gene fusions involving the ERG gene. Recently, N-terminal epitope-targeted mouse and a C-terminal epitope-targeted rabbit monoclonal anti-ERG antibody (ERG-MAbs) have been introduced for the detection of the ERG protein. Independent studies reported that immunohistochemistry (IHC) with both ERG-MAbs highly correlates with the underlying ERG gene rearrangement status. However, comparative studies of both antibodies are lacking. Here, we are among the first to compare the mouse ERGMAb with the rabbit ERG-MAb for their concordance on the same PCa cohort. Furthermore, we assessed whether the ERG protein expression is conserved in lymph node and distant PCa metastases. METHODS: We evaluated tissue microarrays of 278 specimens containing 265 localized PCa, 29 lymph node, 30 distant metastases and 13 normal prostatic tissues. We correlated ERG protein expression with ERG rearrangement status using an ERG break-apart fluorescence in-situ hybridization assay and IHC of both ERG-MAbs. RESULTS: ERG expression and ERG rearrangement status were highly concordant regardless of whether the mouse or rabbit ERG-MAb was used (97.8% versus 98.6%, respectively). Of interest, both ERG antibodies reliably detected the ERG expression in lymph node and distant PCa metastases, of which a subset underwent decalcification. Lymphocytes only revealed immunoreactivity using the rabbit ERG-MAb. If ERG protein expression was present in localized PCa, we observed the same pattern in the corresponding lymph node metastases. CONCLUSIONS: By demonstrating a broad applicability of IHC to study ERG protein expression using either antibody, this study adds an important step toward a facilitated routine clinical application. Further, we demonstrate that the clonal nature of the ERG rearrangement is not restricted to the genomic level, but proceeds in the proteome. Together, our results simplify future efforts to further eliucidate the biological role of ERG in PCa.
INTRODUCTION
The discovery of highly prevalent and recurrent gene rearrangements in prostate cancers (PCa) challenged previously assumed paradigms, and prompted detailed examination of their biological role, diagnostic and therapeutic potentials. 1 --3 The most prominent gene rearrangement in PCa arises between the androgen-regulated serine protease TMPRSS2 and the transcription factor ERG, resulting in an overexpression of a truncated oncoprotein. 2,4 --6 Depending on factors, such as, cohort design (PSA-screened PCa versus incidentally diagnosed PCa), zonal tumor origin (PCa originating from the transitional zone versus PCa originating from the peripheral zone) 7, 8 and various histologic variants of PCa, 9 --12 ERG rearrangements occur in 15 --80% of PCa. Furthermore, despite its high prevalence and clonal nature, 13 --17 the ERG rearrangement is highly specific to PCa. 18 Thus, a diagnostic as well as companion diagnostic utilization of the ERG rearrangement in PCa is imminent, whereas a prognostic and predictive relevance is still controversial. Of interest, within the last 1 year, ERG immunohistochemistry (IHC) has been introduced as a promising tool to detect an ERG expression on the protein level. So far, two monoclonal ERGspecific antibodies (that is, mouse monoclonal anti-ERG antibody (ERG-MAb) and rabbit ERG-MAb) have been established on prostatic tissues. Furusato et al. 19 reported a highly specific mouse ERG-MAb performing a comprehensive evaluation of ERG protein expression using whole mount prostate sections from 132 PCa cases. The ERG protein expression pattern showed a strong concordance with ERG fusion transcripts by branched DNA assay or ERG rearrangement by fluorescence in-situ hybridization (FISH) in selected specimens. By IHC using a rabbit ERG-MAb, Park et al. and van Leenders et al. have provided a comprehensive data showing that virtually all ERG rearranged PCa exhibit an ERG overexpression on the transcriptional and translational level. 20, 21 He et al.
22
confirmed the feasibility of the ERG IHC on an independent cohort containing a broader spectrum of prostatic lesions. In this study, we are among the first to compare the mouse ERG-MAb with the rabbit ERG-MAb and for their concordance on the same cohort of 265 PCa specimens, and matched these results with the respective ERG rearrangement status as defined by FISH. Furthermore, we assessed whether the ERG protein expression is conserved in lymph node and distant PCa metastases, of which a subset underwent decalcification.
MATERIALS AND METHODS Cohort
We assessed 265 PCa specimens for their ERG rearrangement status and ERG protein expression levels under an approved protocol from the University Hospital of Tuebingen. In detail, the cohort comprises 206 localized PCa samples, 29 lymph node metastases and 30 distant metastases. For 16 localized PCa specimens matching lymph node metastases were available. Among the distant metastases, 26 were of osseous origin and 4 were derived from the brain. Furthermore, 13 benign prostatic specimens were included. Patients were diagnosed and treated at the University Hospital of Tuebingen.
Decalcification
All prostatic specimens from osseous origin were decalcified by using the chelating agent EDTA. We used a 10% EDTA solution in distilled water (pH 7.4), for a period of 1 --3 weeks at 4 1C, depending on degree of mineralization. EDTA was replaced every week. After decalcification, specimens were routinely processed and embedded in paraffin.
Tissue microarray construction FISH and IHC experiments were performed on tissue microarrays (TMA). TMA construction was performed as described earlier. 12, 18 Briefly, formalinfixed paraffin-embedded PCa tissue blocks were sectioned at 3 mm thick sections, mounted on slides and stained with haematoxylin and eosin. Prior to TMA construction, representative cancer areas were marked by a pathologist (S P). Three cores, each 0.6 mm in diameter, were taken from the corresponding donor block and placed into a TMA recipient block using a semiautomatic tissue arrayer (Beecher Instruments, Sun Prairie, WI, USA). Of the resulting TMA, tissue sections (3 mm thick) were cut and placed onto superfrost slides.
ERG break-apart fluorescence in-situ hybridization assay A previously described ERG break-apart FISH assay was used to detect the ERG rearrangement at the chromosomal level on formalin-fixed paraffinembedded specimens. 1, 13 In short, this assay employs a split-signal approach, with two probes spanning the ERG locus. BAC clones RP11-24A11 were used for centromeric labelling with biotin and RP11-372O17 for telomeric labelling with digoxigenin. This FISH assay allows for ERG rearrangement status assessment (that is, rearrangement versus no rearrangement of ERG). The assay is also capable of differentiating between two different mechanisms of ERG rearrangement (that is, ERG rearrangement through deletion versus ERG rearrangement through insertion) (Figures 1e --f) . The samples were analysed under a 63 Â oil immersion objective using a fluorescence microscope (Zeiss, Jena, Germany) equipped with appropriate filters, a charge-coupled device camera and the FISH imaging and capturing software Metafer 4 (Metasystems, Altlussheim, Germany). The evaluation of the tests was carried out independently by two experienced observers (V J S and M B). At least 100 nuclei per case were evaluated.
IHC
Sections mounted on superfrost slides were deparaffinized. IHC was conducted with the Ventana Discovery XT automated staining system (Ventana Medical Systems, Tucson, AZ, USA) using Ventana reagents. The following clones and primary antibodies were used: anti-ERG rabbit monoclonal antibody (1:100 dilution, clone EPR3864, Abcam, Cambridge, MA, USA) 21 and anti-ERG mouse monoclonal antibody (1:1000 dilution, CPDR ERG-MAb, clone 9FY, CPDR, Rochville, MD, USA). 19 Dilution was Figure 1 . A lymph node metastasis of an ERG-rearranged prostate cancer (PCa) (arrowheads) stained using the mouse monoclonal anti-ERG antibody (ERG-MAb) (a) and the rabbit ERG-MAb (b), respectively. Follicular lymphocytes (arrows) stained positively using the rabbit ERG-MAb. Sinosoidal histiocytes (white arrowheads) within a lymph node strongly express endogenous ERG protein using the rabbit ERG-MAb (c), but not with the mouse ERG-MAb (not shown). A decalcified vertebral metastasis (arrowheads) of an ERG-rearranged PCa-expressing ERG protein, using the rabbit ERG-MAb (d). Notably, the mouse ERG-MAb works equally good in a decalcified setting and results in the same expression pattern (not shown). Representative images of the ERG break-apart fluorescence in-situ hybridization (FISH) assay as used for the indirect detection of ERG rearrangements (e --g): interphase nuclei displaying a wild-type ERG status (e), a heterozygous ERG rearrangement through deletion (f ) and a heterozygous ERG rearrangement through insertion (g).
performed by using a Ventana diluent. Heat-induced epitope retrieval was performed for both anti-ERG antibodies. Primary antibodies were incubated for 60 min at room temperature. For IHC using anti-ERG rabbit monoclonal antibody (rabbit ERG-MAb), a secondary antibody (UltraMap anti-Rabbit HRP; Ventana Medical Systems, Tucson, AZ, USA) was applied for 16 min at room temperature. For IHC of the anti-ERG mouse monoclonal antibody (mouse ERG-MAb), a secondary antibody (UltraMap anti-Mouse HRP) was applied for 16 min at room temperature. Secondary antibody detection was performed by using the ChromoMap DAB detection kit (Ventana Medical Systems). Slides were counterstained with Hematoxylin II for 8 min followed by Bluing Reagent (Ventana Medical Systems) for 4 min at 37 1C.
The samples were analyzed under a 10 Â dry objective using a standard bright field microscope. The evaluation of the tests was carried out independently by two experienced observers and blinded to the ERG rearrangement status (M B & D G). Nuclear immunoreactivity was scored as negative, weak, moderate or strong. As the vast majority of immunoreactive PCa specimens showed a homogeneous intensity in most tumor cells, any nuclear immunoreactivity of weak, moderate or strong intensity was considered to be positive for ERG protein expression. Strongly ERG protein expressing vascular endothelia was used as an intrinsic positive control for the staining procedure.
Bioinformatics analysis
The amino-acid sequence of ERG was retrieved from the NCBI database. The sequence was analyzed to map the exon locations within the protein by using the Ensembl Genome Browser. The peptide regions of the antibodies were matched with the amino-acid sequence of ERG (NM_004449).
Mouse 
RESULTS
A total of 278 samples were assessed for the ERG rearrangement and ERG protein expression, consisting of 206 localized PCa samples, 29 lymph node metastases, 30 distant metastases and 13 benign prostatic tissues. Among the distant metastases, 26 were of osseous origin and 4 were derived from brain.
By FISH analysis, ERG rearrangements could be detected in 45.3% (120/265 cases) of PCa specimens. Within these cases, 69.2% (83/120) harbored an ERG rearrangement through deletion and 30.8% (37/120) harbored an ERG rearrangement through insertion. As expected, none of the 13 benign samples showed evidence of an ERG rearrangement. Among the lymph node and distant metastases, ERG rearrangements could be detected in 24.1% (7/29) and 26.7% (8/30), respectively. ERG rearrangement status was conserved in all matching lymph node metastases (43.8%, 7/16).
Using the rabbit ERG-MAb, ERG protein expression was detected in 44.5% (118/265) of PCa specimens and 0% (0/13) of benign prostatic tissues. Using the mouse ERG-MAb ERG protein expression was found in 45.3% (120/265) of PCa specimens and 0% (0/20) of benign prostatic tissues.
Assessing the concordance between ERG protein expression levels and ERG rearrangement status (that is, positive ERG protein expression and positive ERG rearrangement status versus negative ERG protein expression and no ERG rearrangement versus discrepant results), we found a highly significant correlation between ERG rearrangement status and ERG protein expression status for both the rabbit ERG-MAb and mouse ERG-MAb (Pearson's correlation coefficient 0.971 and 0.956, respectively; Po0.001). Using the rabbit ERG-MAb, ERG protein expression correctly predicted an ERG rearrangement status in 98.6% (274/278) of cases, whereas discordant results were seen in four cases. Within these, three cases exhibited no ERG protein expression despite a positive ERG rearrangement status. In one case, a weak ERG protein expression was observed in the PCa tissue without any evidence of an ERG rearrangement, as determined by FISH. Using the mouse ERG-MAb, ERG protein expression correctly predicted the ERG rearrangement status in 97.8% (272/278) of cases. Discordant results were observed in only six cases. Three of these cases did not reveal any ERG protein expression despite harboring the ERG rearrangement. In the remaining three cases, an ERG protein expression was present in the PCa tissue without evidence of an ERG rearrangement. In 100% (7/7) of ERG-overexpressing PCa, the same ERG expression pattern was present in the corresponding lymph node metastases.
Assessing ERG protein expression by using either the rabbit ERG-MAb or the mouse ERG-MAb, a highly significant correlation was observed (Pearson's correlation coefficient 0.985, Po0.001). In 99.2% (276/278) of cases, IHC of either antibody revealed the same ERG protein expression pattern (that is, ERG protein expression versus no ERG protein expression), whereas only in three specimens differing results were observed. In all two cases, the PCa tissue displayed an ERG protein expression using the mouse ERG-MAb, but no ERG protein expression was found by using the rabbit ERG-MAb. Both cases did not exhibit an ERG rearrangement in the FISH analysis.
Despite an ERG protein expression in a considerable number of PCa tissues, a small subset of high-grade prostatic intraepithelial neoplasia revealed a moderate-to-strong ERG protein expression. Interestingly, in all these cases, an ERG-rearranged PCa tumour focus with an at least moderate ERG protein expression was present. In concordance with previous reports, most vascular endothelia displayed a strong expression of the ERG protein, regardless whether in proximity of malignant or benign tissue. Of interest, lymphocytes revealed immunoreactivity using the rabbit ERG-MAb, but not by using the mouse ERG-MAb (Figures 1a and  b) . As expected, FISH analysis could not reveal evidence of an ERG rearrangement in any of the above-mentioned non-neoplastic tissues. Of note, in two lymph node metastases, sinushistiocytes were present exhibiting a strong ERG protein expression (Figure 1c) . Notably, decalcification procedures of the bone metastases had no influence on the staining results (Figure 1d ). Cross tables summarize the correlation between the mouse and rabbit ERG-MAb and underlying ERG rearrangement status. (Table 1 --3) . 
DISCUSSION
Recurrent gene rearrangements involving members of the ETS gene family are a hallmark of PCa. 13 Among these, the most commonly observed and highly PCa-specific event is the promoting linkage of the androgen-regulated gene TMPRSS2 to the oncogenic transcription factor ERG. 18 Other, but rarely observed 5 0 fusions partners of ERG, are SLC45A3 and NDRG1.
2,3
In the vast majority of PCa, ERG rearrangements result in a clonal overexpression of chimeric fusion transcripts encoding truncated variants of the ERG protein. 2,4 --6,23 Consequently, with the recent advent of ERG-specific IHC, a potential clinical utilization of ERG-IHC in PCa is straight forward. 19 --22,24 Two ground-breaking studies by Furusato et confirmed the feasibility of the rabbit ERG-MAb IHC in two independent cohorts containing a wide spectrum of prostatic lesions. 20, 22 Although the recent reports uniformly indicated a high potential for a clinical application of the ERG-IHC in PCa, a comprehensive and comparative side-by-side validation of both antibodies was necessary to perform.
Consequently, the objective of this IHC study was to compare ERG protein expression by using both the mouse ERG-MAb and rabbit ERG-MAb on the same large PCa progression cohort with known ERG rearrangement status. So far, this report is the first to include brain and skeletal metastases. Specifically, we addressed three questions: first, the correlation of ERG protein expression with the ERG rearrangement status; second, whether ERG protein expression was conserved in metastatic ERG rearranged PCa; third, whether ERG IHC expresion is possible on decalcified specimens.
Our results demonstrate that both ERG-MAbs exhibited a high degree of specifity and sensitivity in detecting ERG-rearranged PCa. A positive nuclear immunostaining using either the rabbit ERG-MAb or the mouse ERG-MAb predicted an ERG-rearranged PCa with a sensitivity of 97.5% (specificity 99.4%) and 97.8% (specificity 98.1%), respectively. These findings also account for the assessed lymph node and distant metastatic PCa, where we observed a concordant immunostaining in all cases. Of note, decalcification procedures of the bone metastasis had no influence on staining results (Figure 1d ). Of interest, both ERGMAbs showed a strong ERG expression in vascular endothelia and sinusoidal histiocytes that can be used as an intrinsic positive control for the staining procedure described in this study. As far as the rabbit ERG-MAb is concerned, also lymphocytes qualify as an intrinsic positive control for the ERG immunoreactivity.
Taken together, our results confirm that ERG-IHC allows reliable and robust detection of ERG protein expression in localized and metastatic PCa.
ERG-rearranged PCa express various fusion transcripts. The most frequently observed TMPRSS2-ERG fusion transcript results in a combined expression of exon 1 of TMPRSS2 and exon 4 of ERG.
3,25 --27 According to our bioinformatics analysis, the mouse and the rabbit ERG-MAb detect sequences within ERG-exon 4 and exons 8 --11, respectively. C-terminal amino-acid sequences are well conserved within the truncated oncoprotein variants. Apparently, both ERG-MAbs are similarly applicable to detect the most common truncated ERG proteins. As expected, we showed an almost perfect agreement between ERG protein expression patterns of the two antibodies (98.9%). Comparing ERG protein expression utilising the rabbit and mouse ERG-MAb with the underlying ERG rearrangement status, discordant findings were observed in only six cases. Among these, three cases uniformly (that is, with both the rabbit and mouse ERG-MAb) revealed no immunoreaction despite harboring the ERG rearrangement, suggesting the expression of a highly truncated ERG protein lacking all target binding sites of both ERG-MAbs (for example, transcripts exclusively involving ERG-exons 1 --3 or ERG-exons 5 --7). More likely, our findings provide evidence that a very small subset of ERG-rearranged PCa are not overexpressing fusion transcripts, for example, because of dysfunctional androgen signaling. 28 Alternatively, the negative immunoreaction could be because of a very low protein expression, which would not exceed the detection threshold. One case uniformly displayed a strong immunostaining but no evidence of an ERG rearrangement, suggesting that mechanisms other than the ERG rearrangement may lead to an overexpression of the ERG protein. Lastly, two cases displayed an ERG protein expression by using the mouse ERG-MAb, but no ERG protein expression was found by using the rabbit ERG-MAb. Both cases (weak ERG protein immunostaining) showed no ERG rearrangement. These cases may be because of a weak ERG protein expression, which is independent of an ERG rearrangement, and does not exceed the detection threshold of the rabbit ERG-MAb.
Of note, if the ERG rearrangement and ERG protein expression was present in localized PCa, we observed the same pattern in the corresponding lymph node metastases. These findings provide further insight into recent observations that the ERG rearrangement status within PCa tumor foci shows clonality during disease progression---in contrast to a commonly occurring change of features like androgen receptor, phosphatase and tensin homolog copy number changes or Gleason pattern. 13 --16 In this respect, our results demonstrate that the clonal nature of the ERG rearrangement is not restricted to the genomic and transcriptional levels, but proceeds in the proteome. This observation supports that the ERG rearrangements is rather a driver than a passager event in PCa.
In concordance with previous findings, nuclear expression of the ERG protein was present in endothelial cells. Furthermore, by observing that lymphocytes exclusively revealed immunostaining using the rabbit ERG-MAb, but not using the mouse ERG-MAb, we confirm a recent report by Mohamed et al. 29 ( Figures 1a and b) . Additionally, within lymph nodes, we were the first, to our knowledge, to observe a strong nuclear ERG protein expression in sinushistiocytes (Figure 1c) . The characteristically morphological pattern allowed precise differentiation between mononuclear phagocytes and PCa infiltrates. However, this needs to be kept in mind as a pitfall for the unexperienced observer. A recent multitumor (n ¼ 1864) evaluation of ERG protein expression by mouse ERG-MAb showed that in addition to PCa, ERG protein expression is a highly specific marker for vascular endothelium and vascular tumors. Of note, angiomatoid and cutaneous fibrous histiocytoma both did not exhibit ERG immunoreactivity. 24 In summary, by demonstrating a broad applicability of both, the rabbit and mouse ERG-MAb, we confirm the feasibilty of ERG IHC in PCa. Given the comfort of performing IHC versus FISH, ERG protein-based stratification of PCa in formalin-fixed paraffinembedded tissue and in decalcified material may evolve into a valuable tool for routine diagnostics. Furthermore, results of this study facilitate recent efforts to understand the causative role, diagnostic utility and potential applications for monitoring therapeutic efficacy of ERG and the recurrent gene rearrangements in PCa.
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